A kind of hydroxychloroquine sulfate tablet and preparation method thereof
By using microcrystalline cellulose and calcium biphosphate as fillers, low-substituted hydroxypropyl cellulose as disintegrants, disintegrants were added in batches before and after wet granulation, combining adhesives such as starch slurry and lubricants, the solution was solved The problems of low viscosity and dissolution during the preparation process of hydroxychloroquine sulfate tablets achieve high dissolution and cost control, avoiding organic solvent residues.
Patent Information
- Application Number
- CN202410671830.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-28
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-05-28
AI Technical Summary
The existing hydroxychloroquine sulfate tablets are prone to sticking problems during the preparation process, and the dissolution and production costs are high, and there is a problem of organic solvent residue.
Microcrystalline cellulose and calcium biphosphate are used as fillers, low-substituted hydroxypropyl cellulose is used as disintegrants, and disintegrants are added in batches before and after wet granulation, combined with adhesives such as starch slurry and lubricants, during the preparation process No sticking and no organic solvent residue, reducing production costs.
It has achieved high dissolution, stable quality, controllable production cost, easy to amplify production, and avoided organic solvent residues, solving the problem of sticking.
Smart Images

Figure BDA0004862917520000011 
Figure BDA0004862917520000031 
Figure BDA0004862917520000041
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a hydroxychloroquine sulfate tablet and a preparation method thereof. Background Art
[0002] Hydroxychloroquine sulfate tablets were developed by Sanofi-Aventis US in April 1955 and approved by the US FDA for marketing under the trade name Plaquenil. Currently, this product has been listed in many countries around the world, including Europe and Japan. Whether internationally or domestically, hydroxychloroquine sulfate is mainly sold in the form of hydroxychloroquine sulfate tablets. Clinically, hydroxychloroquine sulfate is used to treat diseases such as malaria, discoid lupus erythematosus, systemic lupus erythematosus, and acute and chronic rheumatic arthritis. Hydroxychloroquine sulfate raw material is a white or slightly yellow crystalline powder, which is easily soluble in water and almost insoluble in ethanol and dichloromethane. Its chemical structural formula is as follows:
[0003]
[0004] Hydroxychloroquine sulfate API is a white or slightly yellow crystalline powder, which is easily soluble in water and highly hygroscopic. When placed in a high humidity environment with a humidity of 75% for 24 hours, the weight gain is as high as 10%. Hydroxychloroquine sulfate easily dissociates into hydroxychloroquine and sulfuric acid after absorbing water. Sulfuric acid is highly corrosive to metal equipment, especially in the tablet preparation process, which is extremely prone to sticking.
[0005] Patent CN102525969B adds pH buffer to wet granulation, and the solubility and stability of the preparation are significantly improved, but this technical solution still has the problem of sticking and punching caused by the hygroscopicity of the raw material in the tablet production process. Patent CN102920674B pre-treats the raw material for wet granulation with anhydrous ethanol, and the hygroscopicity of the raw material after treatment is reduced, but the fluidity of the granulated raw material is poor, and it is necessary to carry out secondary wet granulation with auxiliary materials, which greatly reduces the production efficiency. At the same time, the addition of ethanol introduces residual solvents into the finished product, increasing the cost of detection and central control. Patent CN112494437B solves the hygroscopic problem of the active ingredient hydroxychloroquine compounds by selecting large-particle active ingredients, controlling the type and bulk density of the filler, and thus improving the sticking and punching problem of tableting, but the particle size and bulk density of the raw and auxiliary materials need to be controlled during the preparation process, and the auxiliary materials have high requirements and high production costs. Patent CN113116840B overcomes the process difficulties caused by the strong hygroscopicity of hydroxychloroquine sulfate raw material by involving raw materials, lubricants and other pharmaceutically acceptable excipients in wet granulation. Patent CN114224890B uses pregelatinized starch as a disintegrant, which effectively solves the problem of hydroxychloroquine sulfate particles absorbing moisture and causing tablet sticking. Both of the above patents use lactose as a filler, which is expensive and has high costs.
[0006] In view of the deficiencies in the prior art, the present invention provides a hydroxychloroquine sulfate tablet and a preparation method thereof. The prepared hydroxychloroquine sulfate tablet has the advantages of being not easy to stick, having high solubility, stable quality, no organic solvent residue, simple and easy to obtain auxiliary materials, controllable production cost, easy to scale up production, etc. Summary of the invention
[0007] The invention provides a hydroxychloroquine sulfate tablet and a preparation method thereof. Microcrystalline cellulose and calcium hydrogen phosphate are used as fillers, low-substituted hydroxypropyl cellulose is used as a disintegrant, and the disintegrant is added in batches before and after wet granulation, thereby solving the problem that hydroxychloroquine sulfate is easy to absorb moisture and thus causes tablet sticking. The prepared tablet has high dissolution, stable quality, controllable production cost, and is easy to scale up production.
[0008] To achieve the above object, the present invention adopts the following technical scheme: a hydroxychloroquine sulfate tablet, comprising 60-70% by weight of hydroxychloroquine sulfate, 20-40% by weight of a filler, 1-8% by weight of a binder, 1-10% by weight of a disintegrant, 0.5-3% by weight of a lubricant and a coating.
[0009] The filler is one or more of starch, microcrystalline cellulose, pregelatinized starch, lactose, dextrin, mannitol, sorbitol, calcium sulfate, and calcium hydrogen phosphate, preferably microcrystalline cellulose and calcium hydrogen phosphate.
[0010] The amount of the filler is preferably 20-30%.
[0011] The adhesive is one or more of starch slurry, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, povidone, and polyethylene glycol.
[0012] The amount of the binder used is preferably 1-5%.
[0013] The disintegrant is one or more of pregelatinized starch, sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, and cross-linked polyvinylpyrrolidone, preferably low-substituted hydroxypropyl cellulose.
[0014] The dosage of the disintegrant is preferably 2-5%.
[0015] The lubricant is one or more of magnesium stearate, micro powder silica gel, talcum powder, sodium stearyl fumarate, hydrogenated vegetable oil, and polyethylene glycol.
[0016] The amount of the lubricant is preferably 1-2.5%.
[0017] The coating is a film coating premix.
[0018] The present invention also relates to a method for preparing hydroxychloroquine sulfate tablets, comprising the following preparation steps:
[0019] (1) sieve hydroxychloroquine sulfate, filler and disintegrant through a 50-100 mesh sieve for later use;
[0020] (2) Add the adhesive to water, stir evenly and set aside;
[0021] (3) mixing the sieved hydroxychloroquine sulfate, filler, and part of the disintegrant evenly;
[0022] (4) adding a pre-prepared binder to the above-mentioned mixed material, performing wet granulation, drying in a drying oven, controlling the moisture content of the dry granules to be below 2%, sieving and granulating to obtain solid granules;
[0023] (5) mixing the solid particles, the remaining disintegrant, and the lubricant, and tableting to obtain a tablet core;
[0024] (6) preparing a film coating aqueous solution and coating the above tablet cores to obtain coated tablets.
[0025] The hydroxychloroquine sulfate tablets prepared by the invention use microcrystalline cellulose and calcium hydrogen phosphate as fillers, use low-substituted hydroxypropyl cellulose as a disintegrant, and the disintegrant is added in batches before and after wet granulation. No sticking problem occurs during the preparation process, and the prepared tablets have high dissolution and stable quality. No organic solvent is used during the preparation process, the added auxiliary materials are simple and easy to obtain, the production cost is controllable, and the tablets are easy to scale up for production. DETAILED DESCRIPTION
[0026] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail below in conjunction with specific embodiments.
[0027] Example 1 Filler Type Screening Tablet Specification 200 mg / Tablet
[0028]
[0029] Preparation method:
[0030] (1) Pass hydroxychloroquine sulfate, filler and disintegrant through an 80-mesh sieve for later use;
[0031] (2) Add starch to water, stir evenly, prepare 10% starch slurry, and set aside;
[0032] (3) mixing the sieved hydroxychloroquine sulfate, filler, and part of the disintegrant evenly;
[0033] (4) adding the prepared binder to the above-mentioned mixed material, performing wet granulation, drying in a drying oven, the moisture content of the dry granules is 1.6%, and passing through a 20-mesh sieve to obtain solid granules;
[0034] (5) mixing the solid particles, the remaining disintegrant, and the lubricant, and tableting to obtain a tablet core;
[0035] (6) Prepare an aqueous solution of Opadry and coat the tablet cores with the coating to obtain a coating weight gain of 3% to obtain coated tablets.
[0036] Dissolution determination method: Use 900 mL of water as the dissolution medium, select the paddle method, and the speed is 50 rpm. Take 5.5 mL of liquid at the sampling time of 5, 10, 15, 20, 30, and 45 min, filter, and add 5.5 mL of dissolution medium at the same time. Accurately measure an appropriate amount of the filtrate and quantitatively dilute it with dissolution medium water to about 10 μg·mL -1 Solution, accurately weigh hydroxychloroquine sulfate reference substance, and quantitatively dilute it with dissolution medium to about 10 μg mL -1 The solution was tested for absorbance at an ultraviolet wavelength of 343 nm to calculate the cumulative amount of hydroxychloroquine sulfate tablets dissolved.
[0037] The following table shows whether the tableting process of prescriptions 1-7 is sticky and the dissolution of the tablets.
[0038] prescription Tablet pressing Dissolution(45min) Prescription 1 The tablets are smooth and there is no sticking when pressing the tablets 99.8% Prescription 2 The tablets are not smooth and the tablets are obviously sticky. 92.3% Prescription 3 The tablets are not smooth and the tablets are obviously sticky. 95.2% Prescription 4 The tablets are not smooth and the tablets are obviously sticky. 95.8% Prescription 5 The tablets are not smooth and the tablets are obviously sticky. 93.8% Prescription 6 The tablets are not smooth and the tablets are obviously sticky. 91.7% Prescription 7 The tablets are not smooth and the tablets are obviously sticky. 93.4%
[0039] From the results in the above table, it can be seen that when low-substituted hydroxypropyl cellulose is used as a disintegrant and added in batches before and after wet granulation, and when microcrystalline cellulose and calcium hydrogen phosphate are selected as fillers in Formulation 1, the prepared tablets will not have obvious sticking problems and the dissolution rate in 45 minutes is good. However, when other fillers are selected in Formulations 2-7, obvious sticking problems will occur and the dissolution will be incomplete.
[0040] Example 2 Filler dosage screening Tablet specification 200 mg / tablet
[0041]
[0042]
[0043] The tablet preparation method and dissolution test method are the same as those in Example 1.
[0044] The following table shows whether the tableting process of prescription 1, 8-13 is sticky and the dissolution rate of the tablets.
[0045] prescription Tablet pressing Dissolution(45min) Prescription 1 The tablets are smooth and there is no sticking when pressing the tablets 99.8% Prescription 8 The tablets are not smooth and the tablets stick to the punches. 96.7% Prescription 9 The tablets are smooth and there is no sticking when pressing the tablets 100.2% Prescription 10 The tablets are smooth and there is no sticking when pressing the tablets 99.5% Prescription 11 The tablets are smooth and there is no sticking when pressing the tablets 100.4% Prescription 12 The tablets are not smooth and the tablets stick to the punches. 97.5% Prescription 13 The tablets are not smooth and the tablets stick to the punches. 97.0%
[0046] From the results in the above table, it can be seen that when the mass ratio of microcrystalline cellulose to calcium hydrogen phosphate in prescription 8 is 4:1, the mass ratio of microcrystalline cellulose to calcium hydrogen phosphate in prescription 12 is about 1:1, and the mass ratio of microcrystalline cellulose to calcium hydrogen phosphate in prescription 13 is about 1:2, sticking problems will occur and dissolution is incomplete. Therefore, the weight ratio of microcrystalline cellulose to calcium hydrogen phosphate is selected to be 1.5:1 to 3:1.
[0047] Example 3 Screening of disintegrant types Tablet specification 200 mg / tablet
[0048]
[0049] The tablet preparation method and dissolution test method are the same as those in Example 1.
[0050] The following table shows whether the tableting process of prescriptions 1, 14-17 is sticky and the dissolution of the tablets.
[0051] prescription Tablet pressing Dissolution(45min) Prescription 1 The tablets are smooth and there is no sticking when pressing the tablets 99.8% Prescription 14 The tablets are not smooth and the tablets are obviously sticky. 94.6% Prescription 15 The tablets are not smooth and the tablets are obviously sticky. 93.5% Prescription 16 The tablets are not smooth and the tablets are obviously sticky. 95.8% Prescription 17 The tablets are not smooth and the tablets stick to the punches. 96.8%
[0052] From the results in the above table, it can be seen that in prescription 1, microcrystalline cellulose and calcium hydrogen phosphate are used as fillers, low-substituted hydroxypropyl cellulose is used as a disintegrant, and the disintegrant is added in batches before and after wet granulation. The prepared tablets will not have obvious sticking problems, and the dissolution rate in 45 minutes is good. However, when other disintegrants are selected for prescriptions 14-17, sticking problems will occur, and the dissolution is incomplete.
[0053] Example 4 Screening of disintegrant addition method Tablet specification 200 mg / tablet
[0054]
[0055] The tablet preparation method and dissolution test method are the same as those in Example 1.
[0056] The following table shows whether the tableting process of prescription 1, 18-19 is sticky and the dissolution of the tablets.
[0057] prescription Tablet pressing Dissolution(45min) Prescription 1 The tablets are smooth and there is no sticking when pressing the tablets 99.8% Prescription 18 The tablets are smooth and there is no sticking when pressing the tablets 97.1% Prescription 19 The tablets are not smooth and the tablets stick to the punches. 95.5%
[0058] From the results in the above table, it can be seen that in prescription 1, disintegrants were added in batches before and after wet granulation, and the prepared tablets did not have obvious sticking problems, and the dissolution rate was good at 45 minutes. In prescription 18, disintegrants were added before wet granulation, and there was no sticking problem, but the dissolution was incomplete at 45 minutes. In prescription 19, disintegrants were added after wet granulation, and sticking problems occurred, and the dissolution was incomplete.
[0059] Example 5: Add disintegrant in batches to screen tablet specifications 200 mg / tablet
[0060]
[0061]
[0062] The tablet preparation method and dissolution test method are the same as those in Example 1.
[0063] The following table shows whether the tableting process of prescription 1, 20-21 is sticky and the dissolution of the tablets.
[0064] prescription Tablet pressing Dissolution(45min) Prescription 1 The tablets are smooth and there is no sticking when pressing the tablets 99.8% Prescription 20 The tablets are smooth and there is no sticking when pressing the tablets 100.1% Prescription 21 The tablets are smooth and there is no sticking when pressing the tablets 99.7%
[0065] From the results in the above table, it can be seen that when the amount of disintegrant added in batches before and after wet granulation is within a certain range, there will be no sticking problem and the dissolution is complete.
[0066] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any equivalent substitutions or changes made by those skilled in the art on the basis of the present invention without departing from the essential content of the present invention are all within the protection scope of the present invention.
Claims
1. A method for preparing hydroxychloroquine sulfate tablets, characterized in that, (1) sieving hydroxychloroquine sulfate, filler and disintegrant for later use; (2) mixing the sifted hydroxychloroquine sulfate, filler and part of disintegrant evenly; (3) adding a binder to the above-mentioned mixture, wet granulating, drying and granulating to obtain solid particles; (4) mixing the solid particles, the remaining disintegrant and lubricant, tabletting to obtain a tablet core, and coating the tablet core; wherein the filler is microcrystalline cellulose and calcium hydrogen phosphate, and the weight ratio of microcrystalline cellulose to calcium hydrogen phosphate is 1.5:1 to 3:1; the disintegrant is low-substituted hydroxypropyl cellulose; by weight percentage, the tablet core contains 60-70% of hydroxychloroquine sulfate, 20-30% of filler, 1-5% of binder, 2-5% of disintegrant and 1-2.5% of lubricant.
2. The preparation method of hydroxychloroquine sulfate tablets as claimed in claim 1, wherein The adhesive is one or more of starch slurry, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, povidone, and polyethylene glycol.
3. the preparation method of hydroxychloroquine sulfate tablets as claimed in claim 2, is characterized in that, The adhesive is starch slurry.
4. The preparation method of hydroxychloroquine sulfate tablets as claimed in claim 1, characterized in that, The lubricant is one or more of magnesium stearate, micro powder silica gel, talcum powder, sodium stearyl fumarate, hydrogenated vegetable oil, and polyethylene glycol.
5. The preparation method of hydroxychloroquine sulfate tablets as claimed in claim 4, characterized in that, The lubricant is magnesium stearate.
6. The preparation method of hydroxychloroquine sulfate tablets as claimed in claim 1, characterized in that, The coating is a film coating premix.
7. The preparation method of hydroxychloroquine sulfate tablets as claimed in claim 6, characterized in that, The coating was Opadry.
8. The method for preparing the hydroxychloroquine sulfate tablets according to any one of claims 1 to 7, wherein the specific preparation process is as follows: (1) sieve hydroxychloroquine sulfate, filler and disintegrant through a 50-100 mesh sieve for standby use; (2) add a binder into water, stir evenly and set aside; (3) mix the sieved hydroxychloroquine sulfate, filler and part of the disintegrant evenly; (4) add a pre-prepared binder into the mixed material, perform wet granulation, dry the mixture in a drying oven, control the water content of the dry particles to be below 2%, sieve the whole particles and obtain solid particles; (5) mix the solid particles, the remaining disintegrant and the lubricant, and press the tablets to obtain tablet cores; (6) prepare a film coating aqueous solution, and coat the tablet cores to obtain coated tablets.
9. the hydroxychloroquine sulfate tablet prepared by the preparation method as described in any one of claim 1-8.
Citation Information
Patent Citations
Hydroxychloroquine sulphate solid preparation and preparation method thereof
CN102525969B
Technology for preparing hydroxychloroquine sulfate tablets
CN102920674B
Pharmaceutical compositions, tablets and their preparation methods containing hydroxychloroquine compounds
CN112494437B
A method for preparing hydroxychloroquine sulfate tablets
CN113116840B
A hydroxychloroquine sulfate pharmaceutical composition and its preparation method
CN114224890B
